CVR: 37053678
Y-mAbs Therapeutics A/S is a Danish company of the type Aktieselskab based in Hørsholm, founded in 2015. The company is registered under the industry Forskning og eksperimentel udvikling inden for naturvidenskab og teknik. The management consists of Vincent Sainte-Catherine. The company is owned by Y-mAbs Therapeutics, Inc.. The company has 24 employees. In 2025, the company reported a gross profit of DKK 29,300,371 and a net result of DKK -38,461,598 compared with DKK -12,500,464 the year before. Equity amounted to DKK -163,651,844.
Your company? Claim the profile and show your logo, website and social channels — for free.
Claim this profileVirksomhedens formål er at udvikle lægemidler samen anden hermed forbunden virksomhed.
| Year | Gross Profit | Profit/Loss | Total Assets | Equity | Employees | Report |
|---|---|---|---|---|---|---|
| 2025 | 29.3 mio. | -38.5 mio. | 15 mio. | -163.7 mio. | 53 | |
| 2024 | 74.3 mio. | -12.5 mio. | 26.5 mio. | -125.2 mio. | 56 | |
| 2023 | 70.7 mio. | -27.7 mio. | 56.7 mio. | -112.7 mio. | 59 | |
| 2022 | 82.3 mio. | -85.7 mio. | 22.9 mio. | -84.9 mio. | 101 | |
| 2021 | 67.5 mio. | -42.1 mio. | 61.5 mio. | -39.3 mio. | 88 | |
| 2020 | 82.4 mio. | -1.2 mio. | 52 mio. | 2.8 mio. | 62 | |
| 2019 | 52 mio. | -2.6 mio. | 35.7 mio. | 4 mio. | 36 | |
| 2018 | 28.6 mio. | -4.2 mio. | 17.2 mio. | 1.6 mio. | 19 | |
| 2017 | 13.2 mio. | -2.2 mio. | 10.9 mio. | 808 t. | - |
See the CDS score and get a full credit report with recommended credit limit and payment terms.
Read about the CDS scoreCompared to 1.037 companies in Forskning og eksperimentel udvikling inden for naturvidenskab og teknik
Comparison is based on industry median values
Y-mAbs Therapeutics A/S has published its annual report for 2025. Gross profit came to DKK 29,300,371, and the net result was DKK -38,461,598.
Address changed to Agern Alle 13 13, 2970 Hørsholm (January 29, 2026).
As of December 29, 2025, EY Godkendt Revisionspartnerselskab has been appointed auditor of Y-mAbs Therapeutics A/S.
As of December 29, 2025, PRICEWATERHOUSECOOPERS STATSAUTORISERET REVISIONSPARTNERSELSKAB has stepped down as auditor of Y-mAbs Therapeutics A/S.
As of September 29, 2025, Antoine Bernasconi has joined the board of directors of Y-mAbs Therapeutics A/S.
As of September 29, 2025, Vincent Sainte-Catherine has joined the board of directors of Y-mAbs Therapeutics A/S.
As of September 29, 2025, Julien Forest has joined the board of directors of Y-mAbs Therapeutics A/S.
As of September 29, 2025, Johan Ernst Wedell-Wedellsborg has left the board of directors of Y-mAbs Therapeutics A/S.
As of September 29, 2025, Thomas Gad has left the board of directors of Y-mAbs Therapeutics A/S.
As of September 29, 2025, Michael Joseph Rossi has left the board of directors of Y-mAbs Therapeutics A/S.
As of September 29, 2025, Peter Paul Pfreundschuh has left the board of directors of Y-mAbs Therapeutics A/S.
As of September 29, 2025, Vincent Sainte-Catherine is registered as adm. dir. of Y-mAbs Therapeutics A/S.
As of September 29, 2025, Michael Joseph Rossi has stepped down as adm. dir. of Y-mAbs Therapeutics A/S.
Y-mAbs Therapeutics A/S has published its annual report for 2024. Gross profit came to DKK 74,262,634, and the net result was DKK -12,500,464.
As of May 28, 2025, Peter Paul Pfreundschuh has joined the board of directors of Y-mAbs Therapeutics A/S.
As of July 31, 2024, Thomas Gad has joined the board of directors of Y-mAbs Therapeutics A/S.
As of July 31, 2024, Bo Kruse has left the board of directors of Y-mAbs Therapeutics A/S.
As of July 30, 2024, Thomas Gad has left the board of directors of Y-mAbs Therapeutics A/S.
Y-mAbs Therapeutics A/S has published its annual report for 2023. Gross profit came to DKK 70,656,043, and the net result was DKK -27,748,840.
As of November 29, 2023, Michael Joseph Rossi has joined the board of directors of Y-mAbs Therapeutics A/S.
As of November 28, 2023, Michael Joseph Rossi is registered as adm. dir. of Y-mAbs Therapeutics A/S.
As of November 28, 2023, Thomas Gad has stepped down as adm. dir. of Y-mAbs Therapeutics A/S.
Y-mAbs Therapeutics A/S has published its annual report for 2022. Gross profit came to DKK 82,332,358, and the net result was DKK -85,685,825.
Y-mAbs Therapeutics A/S has published its annual report for 2021. Gross profit came to DKK 67,549,569, and the net result was DKK -42,087,769.
As of May 12, 2022, Johan Ernst Wedell-Wedellsborg has joined the board of directors of Y-mAbs Therapeutics A/S.
As of May 12, 2022, Thomas Gad has joined the board of directors of Y-mAbs Therapeutics A/S.
As of May 12, 2022, Bo Kruse has joined the board of directors of Y-mAbs Therapeutics A/S.
As of May 12, 2022, Claus Juan Møller-San Pedro has left the board of directors of Y-mAbs Therapeutics A/S.
As of May 12, 2022, Thomas Gad is registered as adm. dir. of Y-mAbs Therapeutics A/S.
As of May 12, 2022, Claus Juan Møller-San Pedro has stepped down as director of Y-mAbs Therapeutics A/S.
As of May 11, 2022, Thomas Gad has left the board of directors of Y-mAbs Therapeutics A/S.
As of May 11, 2022, Bo Kruse has left the board of directors of Y-mAbs Therapeutics A/S.
As of October 28, 2021, Bo Kruse has joined the board of directors of Y-mAbs Therapeutics A/S.
As of October 28, 2021, Johan Ernst Wedell-Wedellsborg has left the board of directors of Y-mAbs Therapeutics A/S.
As of October 28, 2021, Ashutosh Tyagi has left the board of directors of Y-mAbs Therapeutics A/S.
As of October 28, 2021, David Neil Gill has left the board of directors of Y-mAbs Therapeutics A/S.
As of October 28, 2021, Jim Irvin Healy has left the board of directors of Y-mAbs Therapeutics A/S.
As of October 28, 2021, Gérard Ber has left the board of directors of Y-mAbs Therapeutics A/S.
As of October 28, 2021, Laura J. Hamill has left the board of directors of Y-mAbs Therapeutics A/S.
Y-mAbs Therapeutics A/S has published its annual report for 2020. Gross profit came to DKK 82,433,523, and the net result was DKK -1,202,417.
As of June 11, 2020, Laura J. Hamill has joined the board of directors of Y-mAbs Therapeutics A/S.
As of June 11, 2020, Gregory Stephen Raskin has left the board of directors of Y-mAbs Therapeutics A/S.
Y-mAbs Therapeutics A/S has published its annual report for 2019. Gross profit came to DKK 52,032,447, and the net result was DKK -2,579,400.
As of December 20, 2019, Bo Kruse has left the board of directors of Y-mAbs Therapeutics A/S.
Y-mAbs Therapeutics A/S has published its annual report for 2018. Gross profit came to DKK 28,598,680, and the net result was DKK -4,193,681.
As of December 18, 2018, Gérard Ber has joined the board of directors of Y-mAbs Therapeutics A/S.
As of December 18, 2018, Michael Joachim Buschle has left the board of directors of Y-mAbs Therapeutics A/S.
Y-mAbs Therapeutics A/S has published its annual report for 2017. Gross profit came to DKK 13,194,221, and the net result was DKK -2,177,894.
As of January 18, 2018, Ashutosh Tyagi has joined the board of directors of Y-mAbs Therapeutics A/S.
As of January 18, 2018, David Neil Gill has joined the board of directors of Y-mAbs Therapeutics A/S.
As of January 18, 2018, Michael Joachim Buschle has joined the board of directors of Y-mAbs Therapeutics A/S.
As of January 18, 2018, Jim Irvin Healy has joined the board of directors of Y-mAbs Therapeutics A/S.
Y-mAbs Therapeutics A/S has published its interim report for the period August 27, 2015 – December 31, 2016.
As of January 20, 2016, Johan Ernst Wedell-Wedellsborg has joined the board of directors of Y-mAbs Therapeutics A/S.
As of January 20, 2016, Gregory Stephen Raskin has joined the board of directors of Y-mAbs Therapeutics A/S.
As of August 27, 2015, PRICEWATERHOUSECOOPERS STATSAUTORISERET REVISIONSPARTNERSELSKAB has been appointed auditor of Y-mAbs Therapeutics A/S.
As of August 27, 2015, Claus Juan Møller-San Pedro has joined the board of directors of Y-mAbs Therapeutics A/S.
As of August 27, 2015, Thomas Gad has joined the board of directors of Y-mAbs Therapeutics A/S.
As of August 27, 2015, Bo Kruse has joined the board of directors of Y-mAbs Therapeutics A/S.
As of August 27, 2015, Claus Juan Møller-San Pedro is registered as director of Y-mAbs Therapeutics A/S.
As of August 27, 2015, is registered as an owner of Y-mAbs Therapeutics A/S with an ownership share of 100%.
Y-mAbs Therapeutics A/S was founded on August 27, 2015.
Companies in the same industry and area
CVR 31591414
CVR 29312206
CVR 29829586
CVR 32551475
CVR 38892304
companydata.dk